| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:Mito-LND
CAS:2361564-49-8
Purity:大于98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-1647117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:(10-(1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxamido)decyl)triphenylphosphonium bromide
CAS:2361564-49-8
Purity:98% Package:1mg;5mg;10mg;25mg;50mg;100mg;250mg; Remarks:BD01449537
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Mito-LND;Mito-Lonidamine,mTOR,Autophagy,Mitochondrial Metabolism,p70S6K,oxidative,MitoLND,Inhibitor,inhibit,mitochondria,Mito LND,anti-invasive,anti-cancer,Reactive Oxygen Species,phosphorylation,AKT,Mito-LND
CAS:2361564-49-8
Purity:98.23% Package:1 mL;10 mg;100 mg;2 mg;200 mg;25 mg;5 mg;50 mg
|
|
| | Mito-LND Basic information |
| Product Name: | Mito-LND | | Synonyms: | Mito-LND;Mito-Loidamine;Mito-Lonidamine,mTOR,Autophagy,Mitochondrial Metabolism,p70S6K,oxidative,MitoLND,Inhibitor,inhibit,mitochondria,Mito LND,anti-invasive,anti-cancer,Reactive Oxygen Species,phosphorylation,AKT,Mito-LND;(10-(1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxamido)decyl)triphenylphosphonium bromide | | CAS: | 2361564-49-8 | | MF: | C43H45BrCl2N3OP | | MW: | 801.63 | | EINECS: | | | Product Categories: | | | Mol File: | 2361564-49-8.mol |  |
| | Mito-LND Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (62.37 mM; Need ultrasonic) | | form | Solid | | color | Off-white to light yellow |
| | Mito-LND Usage And Synthesis |
| Biological Activity | Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells[1].
Mito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 values of 0.74 μM and 0.69 μM, respectively[1].Mito-LND inhibits mitochondrial complex I and II activities with IC50 values of 1.2 μM and 2.4 μM, respectively in H2030BrM3 cells[1]. Mito-LND (1 μM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells[1].Mito-LND (2 μM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling[1].
Mito-LND (7.5 μmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) treatment markedly enhanced potency against both lung cancer progression and metastasis[1]. Mito-LND also decreases the rate of growth of A549 tumor xenografts[1].Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells[1]. | | References | [1]. Gang Cheng, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10(1):2205. |
| | Mito-LND Preparation Products And Raw materials |
|